Gregory J. Dore

42.0k total citations · 11 hit papers
508 papers, 23.4k citations indexed

About

Gregory J. Dore is a scholar working on Epidemiology, Hepatology and Infectious Diseases. According to data from OpenAlex, Gregory J. Dore has authored 508 papers receiving a total of 23.4k indexed citations (citations by other indexed papers that have themselves been cited), including 425 papers in Epidemiology, 422 papers in Hepatology and 120 papers in Infectious Diseases. Recurrent topics in Gregory J. Dore's work include Hepatitis C virus research (418 papers), Hepatitis B Virus Studies (270 papers) and Liver Disease Diagnosis and Treatment (223 papers). Gregory J. Dore is often cited by papers focused on Hepatitis C virus research (418 papers), Hepatitis B Virus Studies (270 papers) and Liver Disease Diagnosis and Treatment (223 papers). Gregory J. Dore collaborates with scholars based in Australia, United States and Canada. Gregory J. Dore's co-authors include Jason Grebely, John Kaldor, Behzad Hajarizadeh, Matthew Law, Gail Matthews, Hla‐Hla Thein, Janaki Amin, Andrew R. Lloyd, Murray Krahn and J. Micallef and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Nature Medicine.

In The Last Decade

Gregory J. Dore

490 papers receiving 22.7k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

IL28B is associated with response to chronic hepatitis C interferon-α and ribavirin therapy

2009 1.5k citations Gregory J. Dore, Jacob George et al. profile →
Epidemiology and natural history of HCV infection

2013 755 citations Behzad Hajarizadeh, Jason Grebely et al. profile →
Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies

2005 662 citations John Kaldor, Gregory J. Dore et al. Journal of Viral Hepatitis profile →
Estimation of stage‐specific fibrosis progression rates in chronic hepatitis C virus infection

2008 635 citations Gregory J. Dore et al. profile →
Immunological dysfunction persists for 8 months following initial mild-to-moderate SARS-CoV-2 infection

2022 584 citations Chansavath Phetsouphanh, D.R. Darley et al. Nature Immunology profile →
Hepatitis C virus treatment for prevention among people who inject drugs: Modeling treatment scale-up in the age of direct-acting antivirals

2013 368 citations Peter Vickerman, Jason Grebely et al. profile →
Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy: A systematic review, meta-analyses, and meta-regression

2017 344 citations Reem Waziry, Behzad Hajarizadeh et al. Journal of Hepatology profile →
Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial

2014 333 citations Gregory J. Dore et al. profile →
Restrictions for Medicaid Reimbursement of Sofosbuvir for the Treatment of Hepatitis C Virus Infection in the United States

2015 326 citations Jason Grebely, Gregory J. Dore et al. profile →
Epidemiology of injecting drug use, prevalence of injecting-related harm, and exposure to behavioural and environmental risks among people who inject drugs: a systematic review

2023 109 citations Louisa Degenhardt, Alice Wheeler et al. profile →
Hepatitis C

2023 81 citations Marianne Martinello, Gregory J. Dore et al. profile →

Peers

Countries citing papers authored by Gregory J. Dore

Since Specialization

Citations

This map shows the geographic impact of Gregory J. Dore's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gregory J. Dore with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gregory J. Dore more than expected).

Fields of papers citing papers by Gregory J. Dore

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gregory J. Dore. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gregory J. Dore. The network helps show where Gregory J. Dore may publish in the future.

Co-authorship network of co-authors of Gregory J. Dore

This figure shows the co-authorship network connecting the top 25 collaborators of Gregory J. Dore. A scholar is included among the top collaborators of Gregory J. Dore based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gregory J. Dore. Gregory J. Dore is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Monitoring hepatitis C elimination among people who inject drugs: A broader approach is required 2025 ·International Journal of Drug Policy ·Gregory J. Dore	0
2	Prioritising viral hepatitis elimination to prevent hepatocellular carcinoma: A public health approach for effective preventive hepatology 2025 ·JHEP Reports ·Dana Ivancovsky‐Wajcman, (unknown), Camila A Picchio, (unknown), Geoffrey Dusheiko, Zobair M. Younossi, John Dillon, (unknown), Homie Razavi, Massimo Colombo, Achim Kautz, Gregory J. Dore, Jeffrey V. Lazarus	0
3	Applying a stigma and time framework to facilitate equitable access to hepatitis C care among women who inject drugs: The ETHOS Engage Study 2024 ·International Journal of Drug Policy ·Alison D. Marshall, Jake Rance, Gregory J. Dore, Jason Grebely, (unknown)	0
4	Utilising integrated bio-behavioural surveillance (IBBS) to investigate declining hepatitis C antibody prevalence among people who inject drugs in the Australian Needle and Syringe Program Survey 2024 ·International Journal of Drug Policy ·Lisa Maher, Handan Wand, (unknown), (unknown), (unknown), Robert Kemp, Philip Cunningham, Heidi E. Drummer, Margaret Hellard, John Kaldor, Gregory J. Dore	0
5	Hepatitis C treatment outcome among people in prison: The SToP‐C study 2024 ·Liver International ·Hannah Ryan, Gregory J. Dore, Jason Grebely, Marianne Byrne, Evan B. Cunningham, Marianne Martinello, Andrew R. Lloyd, Behzad Hajarizadeh	2
6	Cascade of care among people with hepatitis B in New South Wales, Australia 2023 ·Journal of Viral Hepatitis ·(unknown), Heather Valerio, Behzad Hajarizadeh, Gail Matthews, Maryam Alavi, Gregory J. Dore	4
7	Temporal change in aetiology and clinical characteristics of hepatocellular carcinoma in a large cohort of patients in New South Wales, Australia 2023 ·Internal Medicine Journal ·(unknown), Gregory J. Dore, (unknown), Mark Danta, (unknown), (unknown), Miriam Levy, Jacob George, Maryam Alavi, Behzad Hajarizadeh	1
8	Controlled Human Infection Model for Hepatitis C Virus Vaccine Development: Trial Design Considerations 2023 ·Clinical Infectious Diseases ·Jordan J. Feld, Julie Bruneau, Gregory J. Dore, Marc G. Ghany, Bettina E. Hansen, Mark Sulkowski, David L. Thomas	6
9	Glecaprevir-pibrentasvir for 4 weeks among people with recent HCV infection: The TARGET3D study 2023 ·JHEP Reports ·Marianne Martinello, Sanjay Bhagani, David Shaw, Chloe Orkin, Graham Cooke, Edward Gane, David Iser, Andrew Ustianowski, Ranjababu Kulasegaram, Catherine Stedman, Elise Tu, Jason Grebely, Gregory J. Dore, Mark Nelson, Gail Matthews	4
10	COVID‐19 vaccine attitudes and facilitators among people in Australia who inject drugs 2023 ·Drug and Alcohol Review ·Olivia Price, Lisa Maher, Paul Dietze, Raimondo Bruno, Sione Crawford, Rachel Sutherland, Caroline Salom, Gregory J. Dore, Amy Peacock	2
11	Immunological dysfunction persists for 8 months following initial mild-to-moderate SARS-CoV-2 infection breakdown → 2022 ·Nature Immunology ·Chansavath Phetsouphanh, D.R. Darley, Daniel B. Wilson, Annett Howe, C. Mee Ling Munier, Sheila K. Patel, Jennifer A. Juno, Louise M. Burrell, Stephen J. Kent, Gregory J. Dore, Anthony D. Kelleher, Gail Matthews	584
12	Nafamostat Mesylate for Treatment of COVID-19 in Hospitalised Patients: A Structured, Narrative Review 2022 ·Clinical Pharmacokinetics ·(unknown), Steven Y. C. Tong, Justin T. Denholm, Gregory J. Dore, Asha C Bowen, Sharon R. Lewin, Balasubramanian Venkatesh, Thomas Hills, Zoe McQuilten, David L. Paterson, Susan C. Morpeth, Jason A. Roberts	17
13	Interventions to enhance testing and linkage to treatment for hepatitis C infection for people who inject drugs: A systematic review and meta-analysis 2022 ·International Journal of Drug Policy ·Evan B. Cunningham, Alice Wheeler, Behzad Hajarizadeh, Clare E. French, Rachel Roche, Alison D. Marshall, Guillaume Fontaine, Anna Conway, Sahar Bajis, Braulio M. Valencia, Justin Presseau, John W. Ward, Louisa Degenhardt, Gregory J. Dore, Matthew Hickman, Peter Vickerman, Jason Grebely	31
14	Author Correction: AP-1 imprints a reversible transcriptional programme of senescent cells 2020 ·Nature Cell Biology ·Ricardo Iván Martínez‐Zamudio, Pierre‐François Roux, (unknown), Lucas Robinson, Gregory J. Dore, Bin Sun, Dimitri Belenki, Maja Milanovic, Utz Herbig, Clemens A. Schmitt, Jesús Gil, Oliver Bischof	1
15	AP-1 imprints a reversible transcriptional programme of senescent cells 2020 ·Nature Cell Biology ·Ricardo Iván Martínez‐Zamudio, Pierre‐François Roux, (unknown), Lucas Robinson, Gregory J. Dore, Bin Sun, Dimitri Belenki, Maja Milanovic, Utz Herbig, Clemens A. Schmitt, Jesús Gil, Oliver Bischof	123
16	Screening Emergency Admissions at Risk of Chronic Hepatitis C (SEARCH) to diagnose or ‘re‐diagnose’ infections is effective in Australia 2020 ·Journal of Viral Hepatitis ·David Prince, (unknown), Melissa A. Fraser, Frank Alvaro, Michael Maley, Hong Foo, Paul M Middleton, Scott A. Davison, Gregory J. Dore, Geoffrey W. McCaughan, Miriam Levy	13
17	Hepatitis C reinfection after successful antiviral treatment among people who inject drugs: A meta-analysis 2019 ·Journal of Hepatology ·Behzad Hajarizadeh, Evan B. Cunningham, Heather Valerio, Marianne Martinello, Matthew Law, Naveed Z. Janjua, Håvard Midgard, Olav Dalgård, John Dillon, Matthew Hickman, Julie Bruneau, Gregory J. Dore, Jason Grebely	114
18	Evaluation of a Hepatitis C Virus Core Antigen Assay in Plasma and Dried Blood Spot Samples 2018 ·Journal of Molecular Diagnostics ·F. Lamoury, Behzad Hajarizadeh, (unknown), (unknown), Camelia Quek, Philip Cunningham, Beth Catlett, Gavin Cloherty, Philippa Marks, Janaki Amin, Jason Grebely, Gregory J. Dore, Tanya Applegate	19
19	Determinants of survival following hepatocellular carcinoma in Egyptian patients with untreated chronic HCV infection in the pre-DAA era 2018 ·Arab Journal of Gastroenterology ·Reem Waziry, Asmaa Gomaa, Imam Waked, Gregory J. Dore	8
20	Trends in hepatocellular carcinoma incidence and survival among people with hepatitis C: An international study 2017 ·Journal of Viral Hepatitis ·Maryam Alavi, Naveed Z. Janjua, Mei Chong, Jason Grebely, Esther Aspinall, Hamish Innes, Heather Valerio, Behzad Hajarizadeh, P C Hayes, Mel Krajden, Janaki Amin, Matthew Law, Jacob George, David Goldberg, Sharon Hutchinson, Gregory J. Dore	15

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact